Form 8-K - Current report:
SEC Accession No. 0001104659-25-061203
Filing Date
2025-06-20
Accepted
2025-06-20 16:44:02
Documents
14
Period of Report
2025-06-20
Items
Item 8.01: Other Events
Item 9.01: Financial Statements and Exhibits

Document Format Files

Seq Description Document Type Size
1 FORM 8-K tm2518362d1_8k.htm   iXBRL 8-K 29525
2 EXHIBIT 5.1 tm2518362d1_ex5-1.htm EX-5.1 10873
3 GRAPHIC tm2518362d1_ex5-1img01.jpg GRAPHIC 3243
  Complete submission text file 0001104659-25-061203.txt   215819

Data Files

Seq Description Document Type Size
4 XBRL TAXONOMY EXTENSION SCHEMA syn-20250620.xsd EX-101.SCH 3041
5 XBRL TAXONOMY EXTENSION LABEL LINKBASE syn-20250620_lab.xml EX-101.LAB 34239
6 XBRL TAXONOMY EXTENSION PRESENTATION LINKBASE syn-20250620_pre.xml EX-101.PRE 22377
16 EXTRACTED XBRL INSTANCE DOCUMENT tm2518362d1_8k_htm.xml XML 3692
Mailing Address 9605 MEDICAL CENTER DRIVE SUITE 270 ROCKVILLE MD 20850
Business Address 9605 MEDICAL CENTER DRIVE SUITE 270 ROCKVILLE MD 20850 (734) 332-7800
Theriva Biologics, Inc. (Filer) CIK: 0000894158 (see all company filings)

EIN.: 133808303 | State of Incorp.: NV | Fiscal Year End: 1231
Type: 8-K | Act: 34 | File No.: 001-12584 | Film No.: 251062030
SIC: 2834 Pharmaceutical Preparations
(CF Office: 03 Life Sciences)